Elizabeth Jones on January 27, 2026 1:46 am I like the balance sheet here—less leverage than peers. Reply
Elijah Jackson on January 27, 2026 1:52 am If AISC keeps dropping, this becomes investable for me. Reply
Ava Miller on January 27, 2026 1:54 am Uranium names keep pushing higher—supply still tight into 2026. Reply
Robert Hernandez on January 27, 2026 1:56 am If AISC keeps dropping, this becomes investable for me. Reply
Mary Jackson on January 27, 2026 1:56 am Interesting update on Domestic Attacks will Target Hospitals. Curious how the grades will trend next quarter. Reply
Isabella Smith on January 27, 2026 1:57 am Interesting update on Domestic Attacks will Target Hospitals. Curious how the grades will trend next quarter. Reply
Robert Rodriguez on January 27, 2026 1:58 am Nice to see insider buying—usually a good signal in this space. Reply
Elizabeth Taylor on January 27, 2026 1:58 am The cost guidance is better than expected. If they deliver, the stock could rerate. Reply
Lucas Smith on January 27, 2026 1:58 am The cost guidance is better than expected. If they deliver, the stock could rerate. Reply
Robert Q. Garcia on January 27, 2026 2:00 am Silver leverage is strong here; beta cuts both ways though. Reply
17 Comments
I like the balance sheet here—less leverage than peers.
Good point. Watching costs and grades closely.
If AISC keeps dropping, this becomes investable for me.
Good point. Watching costs and grades closely.
Uranium names keep pushing higher—supply still tight into 2026.
Good point. Watching costs and grades closely.
If AISC keeps dropping, this becomes investable for me.
Interesting update on Domestic Attacks will Target Hospitals. Curious how the grades will trend next quarter.
Interesting update on Domestic Attacks will Target Hospitals. Curious how the grades will trend next quarter.
Good point. Watching costs and grades closely.
Nice to see insider buying—usually a good signal in this space.
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
Silver leverage is strong here; beta cuts both ways though.